
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
At the upcoming DIA 2018 meeting, Tufts Center for the Study of Drug Development will preview its study findings on the root causes for delays and inefficiencies impacting trial timelines. Through this study, Tufts spoke with executives to learn about the top challenges and opportunities in clinical data management.
Read the full release






